Active — Not RecruitingNot Applicable

LIBERTY: Liquid Biopsy to Diagnose and Monitor CNS Involvement in High-risk B Cell Non-Hodgkin Lymphoma

Switzerland64 participantsStarted 2024-03-12

Plain-language summary

Prevention and treatment of CNS relapse remains a great unmet clinical need in the management of aggressive B-NHL. Hence, investigating novel diagnostic tests is of paramount importance to improve risk-stratification of lymphoma patients at diagnosis, as is the evaluation of novel therapeutic approaches that may prevent and / or treat CNS recurrence. Based on the highlighted evidence, the investigators hypothesize that ctDNA detected within the CSF could potentially improve the detection rate of CNS involvement and consequently improve patients' stratification and better discriminate those in need of consolidative CNS prophylaxis on a molecular basis. Similarly, the investigators postulate that CSF ctDNA could be used as a monitoring tool to assess treatment response and guide therapeutic management.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Informed consent as documented by signature before registration and prior to any trial specific procedures, according to Swiss law and ICH E6 regulations Swiss law and ICH GCP E6(R2) regulations before registration. * Histologically and/or cytologically confirmed newly diagnosed lymphomas including the following: * Diffuse large B-cell lymphoma (DLBCL) with at least one of the following characteristics: * CNS IPI \> 4 * Non-GC/ABC subtype with IPI \> 3 * Testicular involvement * Breast involvement * Kidney involvement * Adrenal involvement * Paranasal sinus / orbit involvement * Involvement of ≥ 3 extranodal sites * HIV-positive * Radiological or histological CNS involvement * High-grade B-cell lymphoma with MYC translocation with BCL2 and / or BCL6 (HGBL) * Burkitt lymphoma * Mantle cell lymphoma (blastoid variant or Ki67 \>30% or TP53 mutated) * Primary CNS lymphoma Note: * Aggressive transformation from indolent lymphomas (pretreated or not) are allowed * Patients enrolled in other clinical trials may be included * Patients must be willing to undergo a lumbar puncture at screening * Age ≥ 18 years Exclusion Criteria: * Subtypes of Non-Hodgkin lymphoma (NHL) not fulfilling above mentioned criteria (e.g., indolent lymphoma, T-cell lymphoma) * Relapsing B-NHL * Low/intermediate-risk DLBCL (CNS-IPI \< 4) AND no CNS involvement on imaging * Any prior lymphoma-directed therapy before registration, with the exception of a maxim…

What they're measuring

Sensitivity

Timeframe: at baseline

Trial details

NCT IDNCT06090162

SponsorSwiss Cancer Institute

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-12